Welcome to the TLDR Biotech newsletter!

Our aim is to be your one-stop source for biotech and pharma updates - all with one daily email.

We’re always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), we’d love to hear from you!

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

THE GOOD
Business Development

Sanofi enters into licensing deal with Novavax for $500M cash (excluding future milestones)
Vaccine, Covid - Read more

Maze Therapeutics licenses Pompe treatment to Shionogi, $150M upfront
Small molecule, pompe disease - Read more

Xbrane and Stada license US commercial rights for Lucentis biosimilar
Antibody, AMD - Read more

THE GOOD
Clinical Trials

AnaptysBio phase 3 psoriasis win
Antibody, psoriasis - Read more

THE GOOD
Earnings & Finances

argenx posts strong Q1 growth and aims high for next Vyvgart launch
2024Q1 $398M revenue (83% YoY growth)
Antibody, myasthenia gravis, CIDP - Read more

THE GOOD
Fundraises

iTeos Therapeutics $120M stock offering
Small molecule, antibody, cancer - Read more

Little Sparrow Technologies $3M seed
Medical device, neonatal care - Read more

Alzamend Neuro stock sale, raises $25M
Small molecule, cell-based vaccine, Alzheimer’s, PTSD - Read more

Triomics lands $15M round
AI, clinical trials, cancer - Read more

SPONSORED
Looking to leave the lab and get into sales?

One of the biggest hurdles to overcome in this job market is experience - and the next best thing you can do is get certified in life sciences sales skills.

Succession is running a 4-week “Welcome to Sales Accelerator” to give you the skills you need and help you land your first sales role. Ready to launch your life science sales career? (Spots are filling up for the June cohort.)

THE GOOD
Partnerships

Dyno Therapeutics and NVIDIA partner on AI-powered gene therapy development
AI, gene therapy - Read more

THE GOOD
Politics & Policy

BIOSECURE Act gets some reprieve with 2032 separation mandate
Geopolitics, USA-China relations - Read more

THE GOOD
Research

New gene insertion techniques announced at ASGCT 2024
Gene therapy, gene editing, CRISPR - Read more

Tessera Therapeutics reports gene-editing and in-vivo CAR-T updates
In-vivo, LNP, CAR-T, gene-editing, cancer, sickle cell - Read more

THE BAD
Clinical Trials

Neuralink implant loses a few connections
Brain-computer interface, medical device - Read more

Excision BioTherapeutics Phase 1 HIV miss
Gene-editing therapy, HIV - Read more

THE BAD
Layoffs

Ginkgo Bioworks plans reduction in labor force, facility consolidations
Cell programming, organism engineering - Read more

CDMO bleeding continues with AGC Biologics planning 100 layoffs
CDMO, biologics - Read more

ENJOYING THIS NEWSLETTER?
Consider subscribing.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a monthly subscription to support my continued work on this project.

THE UGLY
Clinical Trials

MacroGenics stock obliterated after reporting 5 patient deaths
Antibody-drug conjugate, cancer - Read more

THE UGLY
Cybersecurity

Ascension hospital operator has “cyber security event” - Read more

THE UGLY
Politics & Policy

USA emergency drug stockpile management criticized
Emergency preparedness - Read more

THE UGLY
Research

Man who received modified pig kidney passes away, “no indication“ it was from the transplant - Read more

DEEP DIVES & HOT TAKES
Clinical trial diversity is lagging - here’s one way we can fix it.

Clinical trial diversity is critical to developing better medicines, but institutional and researcher distrust is holding us back.

So how can we work towards more representative clinical trials? By focusing on informed consent.

Read more here.

You’re all caught up on the latest Pharma & Biotech News!

We want to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send us an email - we want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️

Want to sponsor this newsletter and reach an audience of 100+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here. 🔍